ERP — community confrontation after the JEEP results
This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as April 2026. Evidence tier: Documented record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.
ERP (Shanghai ERP Peptide Biotechnology) drew community pressure in April 2026 over endotoxin testing. Our corpus does not show a general endotoxin problem at ERP: of 43 published endotoxin readings on ERP-labelled product, 42 were low, below quantitation, negative or passing. The exception is one August 2026 report on an ERP-labelled hCG vial, described below.
Timeline:
- March 25, 2026. Two public-submitted Finnrick retatrutide results on ERP dated this day show quantity deviations of −49.5% (finnrick certificate) and +9.3%. Our corpus holds 101 later Finnrick results on ERP.
- April 19, 2026. An analyst’s write-up, “The Trouble with ERP”, reports a community group test of ERP’s SS-31 and criticises how ERP handled buyers who raised the results. It is shared on GLP-1 Forum in the thread “JEEP isn’t only endo concern. ERP would like a word.....”, which ran to 89 posts between April 19 and 21 in our capture. Participants debated what ERP had been asked, what it said, and whether independent endotoxin testing should be expected of high-volume international vendors.
- August 18, 2026. A Janoshik report (#219296, verification key 4PJ5AERCAHQT) on a sample labelled “HCG 5k”, manufacturer “ERP”, batch “Red Cap”, reads “>1000 EU/Vial (1424.920 EU/Vial estimate)”. The report states that values above 1,000 EU/vial are outside the assay’s validated range. We hold it as a screenshot of the verification page shared on Telegram. The client is listed as anonymous, we have not authenticated the report with Janoshik, and “Red Cap” is a cap colour, not a lot number.
What we hold. Our corpus has 38 Finnrick results on ERP product with an endotoxin reading: 21 below the limit of quantitation, 14 low and 3 negative, dated February 26 to September 24, 2026 (query run October 1, 2026). Finnrick records each as submitted by a member of the public rather than by the vendor. None failed. It also holds five published endotoxin readings from other sources: a Janoshik somatropin report at 2.026 EU/vial, Telegram-shared retatrutide and MOTS-c reports below 0.125 EU/mL, a member-submitted retatrutide result recorded as low, and the August hCG report above.
Our corpus does not support a general endotoxin flag on ERP: 42 of 43 published readings through September 24, 2026 were low, below quantitation, negative or passing. The exception is the August 2026 hCG report above the assay's validated range. It is also the only ERP hCG endotoxin reading we hold, so we cannot say whether it reflects that product or one vial. One analyst's account of ERP's response to buyers, and a group test reported by the same author, are recorded under Single-source community reports below.
Evidence tier: Documented record.
Sources: GLP-1 Forum thread, April 19, 2026; “The Trouble with ERP”, April 19, 2026; Finnrick public test records and other published endotoxin reports, including Janoshik #219296 as shared on Telegram, in the TitrateLab COA corpus, checked October 1, 2026.
Related TitrateLab research: ERP, WBS and JKL: Three Names, One Chinese Peptide Supplier? examines the shared ads, product codes and pricing that connect ERP with WBS and JKL.